AI-enabled virtual primary care
K Health
K Health’s current enterprise offering includes dynamic intake, PatientGPT record questions, and clinician care. Patient questioning and institutional routing are distinct functions. The old direct consumer service is historical, and partner-specific privacy and refusal controls remain unverified.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 46 out of 100 toward patient-directed
Health-system enterprise intake, PatientGPT record conversation and virtual care. The discontinued direct consumer service is historical context.
Mixed, institution-led
K Health’s current enterprise offering includes dynamic intake, PatientGPT record questions, and clinician care. Patient questioning and institutional routing are distinct functions. The old direct consumer service is historical, and partner-specific privacy and refusal controls remain unverified.
Patient agency
How this tool changes agency
Record conversation may help patients understand history and prepare questions. The marketing does not establish source citations, correction of extracted context or alternatives to AI intake.
Partner-specific refusal, records correction, provenance and data-use controls remain unverified
Patient agency assessment
Who sets and changes the goal?
PatientGPT offers direct questioning of records, while intake and care routing remain institutionally configured. These should not be collapsed into a single clinician-only function.
What can the patient understand, question, or do?
Record conversation may help patients understand history and prepare questions. The marketing does not establish source citations, correction of extracted context or alternatives to AI intake.
Can the patient evaluate the conditions of use?
Enterprise branding confirms the current deployment model. It does not verify notice within each partner app, sponsor reporting or the consequences of refusal.
Text findings
Conditions of use
Published controls and their limits
Enterprise branding confirms the current deployment model. It does not verify notice within each partner app, sponsor reporting or the consequences of refusal.
What remains unknown?
Not tested or not established
Partner-specific refusal, records correction, provenance and data-use controls remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Partner-specific refusal, records correction, provenance and data-use controls remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Low to moderate, product claims with blocked governance follow-up (AI-assisted draft)